ADPT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADPT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adaptive Biotechnologies does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
The historical data trend for Adaptive Biotechnologies's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adaptive Biotechnologies Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Adaptive Biotechnologies Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Shiller PE Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Adaptive Biotechnologies's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Adaptive Biotechnologies's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Adaptive Biotechnologies does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
Adaptive Biotechnologies (NAS:ADPT) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Adaptive Biotechnologies's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Chad M Robins | director, officer: CEO and Chairman | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Kyle Piskel | officer: Principal Accounting Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Stacy L Taylor | officer: SVP and General Counsel | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102 |
Tycho Peterson | officer: Chief Financial Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109 |
Sharon Benzeno | officer: Chief Commercial Ofc Imm Med | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Francis Lo | officer: Chief People Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Julie Rubinstein | officer: President | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Susan Bobulsky | officer: SVP, Diagnostics, clonoSEQ | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Nitin Sood | officer: Chief Commercial Officer, MRD | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
R Mark Adams | officer: Chief Operating Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Michelle Renee Griffin | director | 19723 NE 65TH LANE, KIRKLAND WA 98033 |
Michael J Pellini | director | 222 DUTTON MILL RD, WILLISTOWN PA 19380 |
Katey Einterz Owen | director | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Harlan S Robins | officer: Chief Scientific Officer | C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102 |
Peter M Neupert | director | 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005 |
From GuruFocus
By GuruFocus News • 02-11-2025
By GuruFocus News • 01-07-2025
By Marketwired • 01-02-2025
By GuruFocus News • 11-07-2024
By GuruFocus News • 02-04-2025
By GuruFocus News • 11-05-2024
By Marketwired • 11-07-2024
By GuruFocus News • 02-12-2025
By GuruFocus News • 02-10-2025
By GuruFocus News • 01-22-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.